A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Bladder CancerMetastatic Bladder CancerUrothelial Carcinoma
Interventions
DRUG

Atezolizumab

DRUG

Gemcitabine

DRUG

Cisplatin

Trial Locations (11)

10010

New York University, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

18103

Lehigh Valley Health Network, Allentown

43210

Ohio State University, Columbus

06102

Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford

Unknown

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER